Chronic Kidney Disease, Left Ventricular Hypertrophy, Secondary Hyperparathyroidism
Conditions
Keywords
CKD 3-4
Brief summary
Left ventricular hypertrophy (LVH) predicts mortality at start of dialysis. Prevention of of LVH is important. It is not known whether secondary hyperparathyroidism might induce LVH. In the present study patients are randomised to 1.25 dihydroxycholecalciferol or no treatment to study the effect on LVH.
Interventions
DRUGAlfacalcidiol
Alfacalcidiol are given to patientwith CKD 3-4 and secondary hyperparathyrodism. The PTH level is lowered to normal range. with increasing dose of alfacalcidiol and are followed for 6 month.
Sponsors
Per Ivarsen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Chronic kidney disease (S-creatinin \> 150 and \< 600 mikroM) * Secondary hyperparathyroidism (Between 3-8 times the upper limit of our PTH assay) * Stable blood pressure during the last 6 months (less than (160/95) * B-hemoglobin \> 6 mmol/l * EKG with sinus rhythm and no sign of Q-wave infarction * Expected follow up 6 month
Exclusion criteria
* Pregnancy * Kidney transplantation * Malignant disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect of dihydroxycholecalciferol on left ventricular hypertrophy | 6 month |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the activity of the renin-angiotensin system | 6 month |
| Changes in left ventricular function | 6 month |
Countries
Denmark
Outcome results
None listed